{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T02:41:30Z","timestamp":1780368090585,"version":"3.54.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,9,21]],"date-time":"2021-09-21T00:00:00Z","timestamp":1632182400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,9,21]],"date-time":"2021-09-21T00:00:00Z","timestamp":1632182400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Alkermes, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s40263-021-00849-2","type":"journal-article","created":{"date-parts":[[2021,9,21]],"date-time":"2021-09-21T10:29:38Z","timestamp":1632220178000},"page":"1123-1135","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Real-World Outcomes and Costs Following 6 Months of Treatment with the Long-Acting Injectable (LAI) Aripiprazole Lauroxil for the Treatment of Schizophrenia"],"prefix":"10.1007","volume":"35","author":[{"given":"John","family":"Lauriello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Weiden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole D.","family":"Gleeson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankit","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Boulanger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krutika","family":"Jariwala-Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Hedgeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy K.","family":"O\u2019Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,21]]},"reference":[{"key":"849_CR1","doi-asserted-by":"crossref","unstructured":"GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789\u2013858.","DOI":"10.1016\/S0140-6736(18)32279-7"},{"issue":"6","key":"849_CR2","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1093\/schbul\/sby058","volume":"44","author":"FJ Charlson","year":"2018","unstructured":"Charlson FJ, Ferrari AJ, Santomauro DF, Diminic S, Stockings E, Scott JG, et al. Global epidemiology and burden of schizophrenia: findings from the Global Burden of Disease study 2016. Schizophr Bull. 2018;44(6):1195\u2013203.","journal-title":"Schizophr Bull"},{"key":"849_CR3","doi-asserted-by":"publisher","first-page":"e91","DOI":"10.1017\/S2045796019000891","volume":"29","author":"H He","year":"2020","unstructured":"He H, Liu Q, Li N, Guo L, Gao F, Bai L, et al. Trends in the incidence and DALYs of schizophrenia at the global, regional and national levels: results from the Global Burden of Disease Study 2017. Epidemiol Psychiatr Sci. 2020;29:e91.","journal-title":"Epidemiol Psychiatr Sci."},{"key":"849_CR4","first-page":"357","volume":"12","author":"HY Chong","year":"2016","unstructured":"Chong HY, Teoh SL, Wu DB, Kotirum S, Chiou CF, Chaiyakunapruk N. Global economic burden of schizophrenia: a systematic review. Neuropsychiatr Dis Treat. 2016;12:357\u201373.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"6","key":"849_CR5","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1001\/jama.2013.13805","volume":"310","author":"CJ Murray","year":"2013","unstructured":"Murray CJ, Atkinson C, Bhalla K, Birbeck G, Burstein R, Chou D, et al. The state of US health, 1990\u20132010: burden of diseases, injuries, and risk factors. JAMA. 2013;310(6):591\u2013608.","journal-title":"JAMA"},{"issue":"6","key":"849_CR6","doi-asserted-by":"publisher","first-page":"764","DOI":"10.4088\/JCP.15m10278","volume":"77","author":"M Cloutier","year":"2016","unstructured":"Cloutier M, Aigbogun MS, Guerin A, Nitulescu R, Ramanakumar AV, Kamat SA, et al. The economic burden of schizophrenia in the United States in 2013. J Clin Psychiatry. 2016;77(6):764\u201371.","journal-title":"J Clin Psychiatry"},{"key":"849_CR7","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/1471-244X-13-50","volume":"13","author":"R Emsley","year":"2013","unstructured":"Emsley R, Chiliza B, Asmal L, Harvey BH. The nature of relapse in schizophrenia. BMC Psychiatry. 2013;13:50.","journal-title":"BMC Psychiatry"},{"issue":"8","key":"849_CR8","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1176\/appi.ps.55.8.886","volume":"55","author":"PJ Weiden","year":"2004","unstructured":"Weiden PJ, Kozma C, Grogg A, Locklear J. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv. 2004;55(8):886\u201391.","journal-title":"Psychiatr Serv"},{"issue":"1","key":"849_CR9","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1093\/schbul\/sbp116","volume":"36","author":"RW Buchanan","year":"2010","unstructured":"Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull. 2010;36(1):71\u201393.","journal-title":"Schizophr Bull"},{"issue":"5","key":"849_CR10","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1007\/s12325-017-0507-x","volume":"34","author":"E Biagi","year":"2017","unstructured":"Biagi E, Capuzzi E, Colmegna F, Mascarini A, Brambilla G, Ornaghi A, et al. Long-acting injectable antipsychotics in schizophrenia: literature review and practical perspective, with a focus on aripiprazole once-monthly. Adv Ther. 2017;34(5):1036\u201348.","journal-title":"Adv Ther"},{"issue":"10","key":"849_CR11","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.4088\/JCP.v67n1008","volume":"67","author":"M Valenstein","year":"2006","unstructured":"Valenstein M, Ganoczy D, McCarthy JF, Myra Kim H, Lee TA, Blow FC. Antipsychotic adherence over time among patients receiving treatment for schizophrenia: a retrospective review. J Clin Psychiatry. 2006;67(10):1542\u201350.","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"849_CR12","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.apnu.2016.09.003","volume":"31","author":"CE Bright","year":"2017","unstructured":"Bright CE. Measuring medication adherence in patients with schizophrenia: an integrative review. Arch Psychiatr Nurs. 2017;31(1):99\u2013110.","journal-title":"Arch Psychiatr Nurs"},{"issue":"Suppl 3","key":"849_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4088\/JCP.15032su1","volume":"77","author":"CU Correll","year":"2016","unstructured":"Correll CU, Citrome L, Haddad PM, Lauriello J, Olfson M, Calloway SM, et al. The use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidence. J Clin Psychiatry. 2016;77(Suppl 3):1\u201324.","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"849_CR14","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s40261-012-0047-8","volume":"33","author":"F Ca\u00f1as","year":"2013","unstructured":"Ca\u00f1as F, Alptekin K, Azorin JM, Dubois V, Emsley R, Garc\u00eda AG, et al. Improving treatment adherence in your patients with schizophrenia: the STAY initiative. Clin Drug Investig. 2013;33(2):97\u2013107.","journal-title":"Clin Drug Investig"},{"issue":"1","key":"849_CR15","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1093\/bmb\/ldv017","volume":"114","author":"J Lally","year":"2015","unstructured":"Lally J, MacCabe JH. Antipsychotic medication in schizophrenia: a review. Br Med Bull. 2015;114(1):169\u201379.","journal-title":"Br Med Bull"},{"issue":"Suppl 4","key":"849_CR16","first-page":"1","volume":"70","author":"DI Velligan","year":"2009","unstructured":"Velligan DI, Weiden PJ, Sajatovic M, Scott J, Carpenter D, Ross R, et al. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry. 2009;70(Suppl 4):1\u201346 ((quiz 7-8)).","journal-title":"J Clin Psychiatry"},{"key":"849_CR17","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2147\/PPA.S124658","volume":"11","author":"DI Velligan","year":"2017","unstructured":"Velligan DI, Sajatovic M, Hatch A, Kramata P, Docherty JP. Why do psychiatric patients stop antipsychotic medication? A systematic review of reasons for nonadherence to medication in patients with serious mental illness. Patient Prefer Adherence. 2017;11:449\u201368.","journal-title":"Patient Prefer Adherence"},{"key":"849_CR18","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.eurpsy.2018.04.004","volume":"52","author":"PM Llorca","year":"2018","unstructured":"Llorca PM, Bobes J, Fleischhacker WW, Heres S, Moore N, Bent-Ennakhil N, et al. Baseline results from the European non-interventional Antipsychotic Long acTing injection in schizOphrenia (ALTO) study. Eur Psychiatry. 2018;52:85\u201394.","journal-title":"Eur Psychiatry"},{"key":"849_CR19","first-page":"219","volume-title":"Comprehensive care of schizophrenia: a textbook of clinical management","author":"PJ Weiden","year":"2012","unstructured":"Weiden PJ, Turkington D. Assessment and management of medication nonadherence in schizophrenia. In: Lieberman JA, Murray RM, editors. Comprehensive care of schizophrenia: a textbook of clinical management. 2nd ed. New York: Oxford University Press; 2012. p. 219\u201343.","edition":"2"},{"issue":"5","key":"849_CR20","first-page":"271278","volume":"41","author":"PJ Weiden","year":"2011","unstructured":"Weiden PJ, Solari H, Kim S, Bishop JR. Long-acting injectable antipsychotics and the management of nonadherence. Psychiatr Ann. 2011;41(5):271278.","journal-title":"Psychiatr Ann"},{"key":"849_CR21","unstructured":"Aristada [package insert]. Waltham, MA: Alkermes, Inc.; 2020 February 2020."},{"issue":"6","key":"849_CR22","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","volume":"45","author":"RA Deyo","year":"1992","unstructured":"Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613\u20139.","journal-title":"J Clin Epidemiol"},{"key":"849_CR23","unstructured":"US Bureau of Labor Statistics. Consumer Price Index Detailed Report Tables: United States Department of Labor; 2020. https:\/\/www.bls.gov\/cpi\/home.htm."},{"issue":"1","key":"849_CR24","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s40801-019-00172-9","volume":"7","author":"C Patel","year":"2020","unstructured":"Patel C, Emond B, Lafeuille MH, C\u00f4t\u00e9-Sergent A, Lefebvre P, Tandon N, et al. Real-world analysis of switching patients with schizophrenia from oral risperidone or oral paliperidone to once-monthly paliperidone palmitate. Drugs Real World Outcomes. 2020;7(1):19\u201329.","journal-title":"Drugs Real World Outcomes."},{"key":"849_CR25","doi-asserted-by":"publisher","first-page":"100587","DOI":"10.1016\/j.curtheres.2020.100587","volume":"92","author":"C Patel","year":"2020","unstructured":"Patel C, Khoury AE, Huang A, Wang L, Bashyal R. Healthcare resource utilization and costs among patients with schizophrenia switching from oral risperidone\/paliperidone to once-monthly paliperidone palmitate: a Veterans Health Administration claims analysis. Curr Ther Res Clin Exp. 2020;92:100587.","journal-title":"Curr Ther Res Clin Exp"},{"issue":"3","key":"849_CR26","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/hup.1108","volume":"25","author":"K Lloyd","year":"2010","unstructured":"Lloyd K, Latif MA, Simpson S, Shrestha KL. Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: efficacy, quality of life and functional outcome. Hum Psychopharmacol. 2010;25(3):243\u201352.","journal-title":"Hum Psychopharmacol"},{"key":"849_CR27","doi-asserted-by":"crossref","unstructured":"Gaebel W, Schreiner A, Bergmans P, de AR, Rouillon F, Cordes J, et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial. Neuropsychopharmacology. 2010;35(12):2367\u201377.","DOI":"10.1038\/npp.2010.111"},{"key":"849_CR28","doi-asserted-by":"publisher","first-page":"212273","DOI":"10.7573\/dic.212273","volume":"5","author":"M Wilson","year":"2016","unstructured":"Wilson M, Gutierrez B, Offord SJ, Blanchette CM, Eramo A, Earnshaw S, et al. Inpatient resource use and costs associated with switching from oral antipsychotics to aripiprazole once-monthly for the treatment of schizophrenia. Drugs Context. 2016;5:212273.","journal-title":"Drugs Context."},{"issue":"3","key":"849_CR29","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1080\/03007995.2018.1560220","volume":"35","author":"B Emond","year":"2019","unstructured":"Emond B, El Khoury AC, Patel C, Pilon D, Morrison L, Zhdanava M, et al. Real-world outcomes post-transition to once-every-3-months paliperidone palmitate in patients with schizophrenia within US commercial plans. Curr Med Res Opin. 2019;35(3):407\u201316.","journal-title":"Curr Med Res Opin"},{"issue":"9","key":"849_CR30","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1016\/j.clinthera.2018.07.011","volume":"40","author":"M DerSarkissian","year":"2018","unstructured":"DerSarkissian M, Lefebvre P, Joshi K, Brown B, Lafeuille MH, Bhak RH, et al. Health care resource utilization and costs associated with transitioning to 3-month paliperidone palmitate among US veterans. Clin Ther. 2018;40(9):1496\u2013508.","journal-title":"Clin Ther"},{"issue":"2","key":"849_CR31","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1080\/13696998.2017.1379412","volume":"21","author":"M Greene","year":"2018","unstructured":"Greene M, Yan T, Chang E, Hartry A, Touya M, Broder MS. Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder. J Med Econ. 2018;21(2):127\u201334.","journal-title":"J Med Econ"},{"key":"849_CR32","doi-asserted-by":"publisher","first-page":"619","DOI":"10.2147\/PPA.S127623","volume":"11","author":"D Pilon","year":"2017","unstructured":"Pilon D, Joshi K, Tandon N, Lafeuille MH, Kamstra RL, Emond B, et al. Treatment patterns in Medicaid patients with schizophrenia initiated on a first- or second-generation long-acting injectable versus oral antipsychotic. Patient Prefer Adherence. 2017;11:619\u201329.","journal-title":"Patient Prefer Adherence"},{"issue":"5","key":"849_CR33","doi-asserted-by":"publisher","first-page":"357","DOI":"10.3111\/13696998.2014.1001514","volume":"18","author":"O Baser","year":"2015","unstructured":"Baser O, Xie L, Pesa J, Durkin M. Healthcare utilization and costs of Veterans Health Administration patients with schizophrenia treated with paliperidone palmitate long-acting injection or oral atypical antipsychotics. J Med Econ. 2015;18(5):357\u201365.","journal-title":"J Med Econ"},{"issue":"11","key":"849_CR34","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1007\/s12325-018-0786-x","volume":"35","author":"A Shah","year":"2018","unstructured":"Shah A, Xie L, Kariburyo F, Zhang Q, Gore M. Treatment patterns, healthcare resource utilization and costs among schizophrenia patients treated with long-acting injectable versus oral antipsychotics. Adv Ther. 2018;35(11):1994\u20132014.","journal-title":"Adv Ther"},{"key":"849_CR35","first-page":"9","volume":"3","author":"X Peng","year":"2011","unstructured":"Peng X, Ascher-Svanum H, Faries D, Conley RR, Schuh KJ. Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophrenia. ClinicoEcon Outcomes Res. 2011;3:9\u201314.","journal-title":"ClinicoEcon Outcomes Res."},{"issue":"8","key":"849_CR36","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1176\/ps.2010.61.8.830","volume":"61","author":"E Khaykin","year":"2010","unstructured":"Khaykin E, Eaton WW, Ford DE, Anthony CB, Daumit GL. Health insurance coverage among persons with schizophrenia in the United States. Psychiatr Serv. 2010;61(8):830\u20134.","journal-title":"Psychiatr Serv"},{"key":"849_CR37","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1478-7547-7-11","volume":"7","author":"DE Faries","year":"2009","unstructured":"Faries DE, Nyhuis AW, Ascher-Svanum H. Methodological issues in assessing changes in costs pre- and post-medication switch: a schizophrenia study example. Cost Eff Resour Alloc. 2009;7:11.","journal-title":"Cost Eff Resour Alloc."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-021-00849-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-021-00849-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-021-00849-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T11:22:59Z","timestamp":1632828179000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-021-00849-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,21]]},"references-count":37,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["849"],"URL":"https:\/\/doi.org\/10.1007\/s40263-021-00849-2","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,21]]},"assertion":[{"value":"17 July 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Alkermes, Inc. The open access fee was paid by Alkermes, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"AKO, CDG, AS, and PJW were employed by Alkermes, Inc., at the time this research was conducted. LB, KJP, and EH were employed by IBM Watson Health at the time this research was conducted and received funding from Alkermes, Inc., to conduct this study. JL is a paid consultant of Alkermes, Inc., although he was not paid for his time on this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All database records are statistically de-identified and certified to be fully compliant with US patient confidentiality requirements set forth in the Health Insurance Portability and Accountability Act of 1996. Because this study used only de-identified patient records and did not involve the collection, use, or transmittal of individually identifiable data, institutional review board approval to conduct this study was not necessary.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The data that support the findings of this study are available from IBM Watson Health. Restrictions apply to the availability of these data, which were used under license for this study.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"JL, CG, LJB, AS, AOS, EH, KJP, PW contributed to the design of the study and interpretation of the data. AOS, EH, KJP, PW, contributed to the data collection and data analysis. All authors critically revised the draft manuscript and approved the final content and are accountable for the work presented.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contribution"}}]}}